2.10
price up icon0.00%   0.00
after-market 시간 외 거래: 2.09 -0.01 -0.48%
loading
전일 마감가:
$2.10
열려 있는:
$2.05
하루 거래량:
62,960
Relative Volume:
0.26
시가총액:
$85.86M
수익:
$2.70M
순이익/손실:
$5.53M
주가수익비율:
19.09
EPS:
0.11
순현금흐름:
$-10.55M
1주 성능:
-1.87%
1개월 성능:
-18.29%
6개월 성능:
-12.86%
1년 성능:
-19.54%
1일 변동 폭
Value
$2.04
$2.115
1주일 범위
Value
$2.04
$2.37
52주 변동 폭
Value
$1.9929
$3.09

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name
명칭
Oramed Pharmaceuticals Inc
Name
전화
646-844-1164
Name
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Name
직원
0
Name
트위터
@OramedPharma
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ORMP's Discussions on Twitter

ORMP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ORMP
Oramed Pharmaceuticals Inc
2.10 85.86M 2.70M 5.53M -10.55M 0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-01-12 다운그레이드 Canaccord Genuity Buy → Hold
2022-02-18 개시 Cantor Fitzgerald Overweight
2021-04-20 개시 Canaccord Genuity Buy
2021-02-09 개시 National Securities Buy
2020-12-03 개시 Alliance Global Partners Buy
2020-03-11 개시 Aegis Capital Buy
2019-09-11 개시 Ladenburg Thalmann Buy
2017-12-11 재개 B. Riley FBR, Inc. Buy
2016-05-26 재확인 FBR Capital Outperform
2015-12-01 재확인 H.C. Wainwright Buy
2015-11-19 개시 FBR Capital Outperform
2015-04-13 재개 MLV & Co Buy
2014-01-30 재확인 Aegis Capital Buy
2014-01-08 재확인 Aegis Capital Buy
2014-01-08 개시 MLV & Co Buy
2013-12-03 개시 Aegis Capital Buy
모두보기

Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스

pulisher
Mar 24, 2025

Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com

Mar 24, 2025
pulisher
Mar 21, 2025

Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 12, 2025

Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal

Mar 12, 2025
pulisher
Mar 11, 2025

Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle

Mar 11, 2025
pulisher
Mar 08, 2025

AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges - Investing.com

Mar 03, 2025
pulisher
Mar 01, 2025

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter

Mar 01, 2025
pulisher
Feb 28, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga

Feb 26, 2025
pulisher
Feb 22, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat

Feb 22, 2025
pulisher
Feb 17, 2025

227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat

Feb 17, 2025
pulisher
Feb 15, 2025

Oramed announces spinoff of protein drug technology - MSN

Feb 15, 2025
pulisher
Feb 12, 2025

OraTech to pioneer oral insulin with $75 million investment - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com

Feb 12, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph

Feb 11, 2025
pulisher
Feb 11, 2025

OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire

Feb 11, 2025
pulisher
Feb 11, 2025

Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

Feb 10, 2025
pulisher
Feb 04, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Feb 04, 2025
pulisher
Jan 31, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average – Here’s Why - Defense World

Jan 31, 2025
pulisher
Jan 24, 2025

Oramed Pharmaceuticals Extends Maturity Date of Senior Secured Promissory Note in Recent Amendment - Defense World

Jan 24, 2025
pulisher
Jan 22, 2025

Oramed Pharmaceuticals extends loan maturity, acquires Scilex shares - Investing.com

Jan 22, 2025
pulisher
Jan 21, 2025

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times

Jan 21, 2025
pulisher
Jan 18, 2025

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat

Jan 18, 2025
pulisher
Jan 14, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World

Jan 14, 2025

Oramed Pharmaceuticals Inc (ORMP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
자본화:     |  볼륨(24시간):